Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.240
-0.020 (-1.59%)
May 12, 2025, 4:00 PM - Market closed
Chemomab Therapeutics Employees
Chemomab Therapeutics had 20 employees as of December 31, 2021.
Employees
20
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$697,250
Market Cap
23.38M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2021 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CMMB News
- 7 days ago - Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025 - GlobeNewsWire
- 14 days ago - Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases - GlobeNewsWire
- 21 days ago - Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences - GlobeNewsWire
- 27 days ago - Chemomab Announces New Medical and Clinical Appointments - GlobeNewsWire
- 6 weeks ago - Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease - Benzinga
- 6 weeks ago - Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers - GlobeNewsWire
- 2 months ago - New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis - GlobeNewsWire
- 2 months ago - Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire